Aisling Capital Management Lp
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$476.3M
Q ending 2026-03-31
Prior quarter
$478.9M
Q ending 2025-12-31
Change
-0.5% QoQ · +65.1% YoY
Positions
13
reported holdings
Largest positions
All 13 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Bridgebio Pharma Inc. (Bbio) | BBIO | Shares | $378.0M | 5.1M |
| Syndax Pharmaceuticals, Inc. (Sndx | SNDX | Shares | $30.8M | 1.3M |
| Monte Rosa Therapeutics Inc (Glue) | GLUE | Shares | $25.6M | 1.6M |
| Bicara Therapeutics Inc. (Bcax) | BCAX | Shares | $11.3M | 569K |
| Bridgebio Oncology Therapeutics (B | BBOT | Shares | $9.1M | 1.0M |
| Compass Pathways Plc (Cmps) | CMPS | Shares | $7.9M | 1.4M |
| Scholar Rock Holding Corporation ( | SRRK | Shares | $3.8M | 77K |
| Biomea Fusion Inc (Bmea) | BMEA | Shares | $3.1M | 2.0M |
| Eupraxia Pharmaceuticals Inc. (Epr | EPRX | Shares | $2.4M | 325K |
| Urogen Pharma Ltd. (Urgn) | Shares | $1.9M | 108K | |
| Aclaris Therapeutics Inc (Acrs) | ACRS | Shares | $1.6M | 434K |
| Marker Therapeutics, Inc. (Mrkr) | MRKR | Shares | $423K | 325K |
| Onkure Therapeutics, Inc. (Okur) | OKUR | Shares | $367K | 89K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.